Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lipponen

Showing results (61-70 of 129) with videos related to

Pageof 13
Sort By:
Anticancer Research|May 1, 1993
Mitotic activity index, volume corrected mitotic index and human papilloma-virus suggestive morphology are not prognostic factors in carcinoma of the oesophagusM Hippeläinen, M Eskelinen, P Lipponen, et al.
European Urology|February 27, 2001
Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancerS Aaltomaa, P Lipponen, M Ala-Opas, et al.
The Prostate|August 1, 1995
Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomasS Vesalainen, P Lipponen, M Talja, et al.
The Journal of Urology|November 1, 1994
Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reactionF Chang, P Lipponen, A Tervahauta, et al.
Anticancer Research|March 1, 1995
Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biologyS Vesalainen, P Lipponen, S Nordling, et al.
European Urology|January 1, 1991
DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinomaM Eskelinen, P Lipponen, R Majapuro, et al.
Anticancer Research|July 1, 1996
A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumourP Lipponen, S Vesalainen, J Kasurinen, et al.
International Journal of Cancer|April 15, 1994
Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinomaP Lipponen, M Eskelinen, K Hietala, et al.
European Urology|April 15, 2000
Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferationP Lipponen, S Aaltomaa, J Kellokoski, et al.
International Journal of Cancer|October 21, 1993
The value of histoquantitative measurements in prognostic assessment of renal adenocarcinomaM Eskelinen, P Lipponen, L Aitto-Oja, et al.
Pageof 13

Showing results (61-70 of 129) with videos related to

Sort By:
Pageof 13
Anticancer Research|May 1, 1993
Mitotic activity index, volume corrected mitotic index and human papilloma-virus suggestive morphology are not prognostic factors in carcinoma of the oesophagusM Hippeläinen, M Eskelinen, P Lipponen, et al.
European Urology|February 27, 2001
Expression and prognostic value of CD44 standard and variant v3 and v6 isoforms in prostate cancerS Aaltomaa, P Lipponen, M Ala-Opas, et al.
The Prostate|August 1, 1995
Nuclear morphometry is of independent prognostic value only in T1 prostatic adenocarcinomasS Vesalainen, P Lipponen, M Talja, et al.
The Journal of Urology|November 1, 1994
Transitional cell carcinoma of the bladder: failure to demonstrate human papillomavirus deoxyribonucleic acid by in situ hybridization and polymerase chain reactionF Chang, P Lipponen, A Tervahauta, et al.
Anticancer Research|March 1, 1995
Results of the primary treatment in T1-3M0 prostatic adenocarcinoma are dependent on tumour biologyS Vesalainen, P Lipponen, S Nordling, et al.
European Urology|January 1, 1991
DNA ploidy, S phase fraction and G2 fraction as prognostic determinants in prostatic adenocarcinomaM Eskelinen, P Lipponen, R Majapuro, et al.
Anticancer Research|July 1, 1996
A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumourP Lipponen, S Vesalainen, J Kasurinen, et al.
International Journal of Cancer|April 15, 1994
Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinomaP Lipponen, M Eskelinen, K Hietala, et al.
European Urology|April 15, 2000
Expression of activator protein 2 in prostate cancer is related to tumor differentiation and cell proliferationP Lipponen, S Aaltomaa, J Kellokoski, et al.
International Journal of Cancer|October 21, 1993
The value of histoquantitative measurements in prognostic assessment of renal adenocarcinomaM Eskelinen, P Lipponen, L Aitto-Oja, et al.
Pageof 13